Business Plan
2028 Vision: "Creating a Chain of Happiness by Being Close to Stakeholders"
Our vision for the fiscal year 2028 is "Creating a Chain of Happiness by Being Close to Stakeholders." Keeping in mind our mission to "support the advancement of drug discovery and medical technology and free humanity from suffering," we aim to create a chain of happiness in the world by generating both economic and social value together with our stakeholders through our business.
Financial KPIs
We have set financial KPIs and goals for the 2028 Vision.
| FY2021 (Actual) (FY2022) At 2028 Vision formulation |
Fiscal 2023 (actual results) (Fiscal year ending March 2024) |
Fiscal 2028 (target) (Fiscal year ending March 2029) |
||
|---|---|---|---|---|
| Growth Indicators | Revenue | 17.74 billion yen | 26.45 billion yen | 50 billion yen |
| Ord. Profit (Ex. FX) |
5.7 billion yen | 6.95 billion yen | 20 billion yen | |
| Ord. Profit Margin (Ex. FX) |
32.2％ | 26.3% | 40.0% | |
| Shareholder return indicators | Dividend payout ratio | 23.4% | 37.6% | 30～40% |
| Capital Return index |
ROE | 40.4% | 18.3 | More than 10% |
| ROIC | 18.4% | 10.3 | More than 10% |
Three Growth Engines for Sustainable Growth
In order to achieve sustainable growth, we have been working to expand our growth engine. Both the non-clinical business using our first engine, the experimental NHP, and the clinical business of our second engine, theSNBL PPD, continue to grow steadily.
Going forward, we will develop the TR business, which leverages our nasal drug delivery platform technology, as a third engine for further growth.
